Atrial fibrillation (AF) is an extremely common clinical problem, and currently available antiarrhythmic drug therapy has limited efficacy and proarrhythmic liability. We have shown previously that detailed mathematical analysis can be used to identify pharmacodynamic properties of Na + -channel-blocking antiarrhythmic drugs to maximize actions on atrial cells during AF (efficacy) and to minimize actions on ventricular cells during sinus rhythm (governing proarrhythmic risk), a property that can be called AF selectivity. Multichannel blocking antiarrhythmics have been found empirically to have a better efficacy/safety relationship. Here, we considered the hypothesis that the addition of K + -channel blockade would enhance the AF selectivity of optimized Na + -channel blockers. We first applied realistic mathematical models of canine cardiomyocyte and tissue electrophysiology, along with statedependent Na + -channel-blocking drug action, and found that adding block of either rapid delayed-rectifier (I Kr ) or ultrarapid delayed-rectifier K + -current increased the AF selectivity achievable with optimized Na + -channel blockers. We then used optical mapping and action potential recording in isolated coronary-perfused canine cardiac tissue preparations to study the effects of the highly selective Na + -channel blocker pilsicainide, alone and along with the IKr blocker dofetilide, to qualitatively test the predictions of the mathematical modeling and found them to be confirmed: Pilsicainide combined with dofetilide had selective rate-dependent atrial Na + -channel blocking activity and enhanced AF-suppressing effectiveness compared with pilsicainide alone. We conclude that K + -channel block potentiates the AF-selective antiarrhythmic effects obtainable with optimized Na + -channel blockade. Combining optimized Na + -channel block with blockade of atrial K + currents is a potentially valuable AF-selective antiarrhythmic drug development strategy, allowing the rationale design of multichannel blocking antiarrhythmics. See p 2203.
Changes in Diet Quality Scores and Risk of Cardiovascular Disease Among US Men and Women
In this study, we evaluated the association between short-and long-term changes in 3 diet quality scores and cardiovascular disease (CVD) risk in a well-established cohorts of US women and men over 24 years. Our findings underscore that, in middle-aged participants, maintaining consistently high adherence to diet quality scores was related to lower CVD risk and individuals with low adherence to diet quality scores in the beginning can still reduce their CVD risk by improving their diet quality, independently of traditional cardiovascular risk factors, at both the short term and long term. This benefit could be easily achieved by improving any of the components describing the Alternative Healthy Eating Index 2010, Alternative Mediterranean Diet score, or the Dietary Approach to Stop Hypertension index. For example, a person with a 20-percentile increase in the Alternative Healthy Eating Index 2010 score (eg, increasing nuts and legumes up to 1 serving per day and not consuming sugar-sweetened beverages and fruit juice daily) over a 4-year period could lower the CVD risk by 9% in the subsequent 4 years. Our analysis looking at short-and long-term diet changes allows a more appropriate and practical evaluation of how dynamic and realistic changes in diet quality are associated with CVD risk. The evaluation of population changes in dietary quality over time and the impact on CVD is essential for better decisions in nutrition and public health policy. Thus, new and stronger strategies should be developed to help the general population improve diet quality to prevent CVD. Success in policy decisions should be tested in future studies. See p 2212.
Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial
A large proportion of cardiovascular events occur among individuals who have normal or even low low-density lipoprotein (LDL) cholesterol. Some of these events may be related to high particle concentrations (numbers) of LDL or other atherogenic lipoproteins (such as very-low-density lipoprotein and intermediate-density lipoprotein). These atherogenic lipoproteins each contain 1 apolipoprotein B molecule, but they represent a heterogeneous group of particles that span a spectrum of size, density, and cholesterol or triglyceride composition. It is unknown whether lipoprotein subfractions contribute to cardiovascular risk among statin-naive individuals or after statin initiation. The present study evaluated a novel method (ion mobility) that directly quantifies lipoprotein particles across the entire lipoprotein spectrum. With the use of ion mobility, baseline and on-treatment lipoprotein subfractions were measured in 11 186 participants in the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, a cohort characterized by low LDL cholesterol but elevated high-sensitivity C-reactive protein. Incident cardiovascular events were not associated with baseline LDL cholesterol but were associated with higher baseline levels of atherogenic particles as assessed by non-high-density lipoprotein cholesterol, apolipoprotein B, and ion mobility-measured non-high-density lipoprotein particles or LDL particles and by select subfractions (primarily large and medium very-low-density lipoprotein and medium to very small LDL). During high-intensity statin therapy, the pattern of lipoprotein subfractions that was associated with residual cardiovascular risk differed from that seen at baseline, with a shift toward more prominent associations for smaller very-low-density lipoprotein and larger LDL subfractions. This may indicate inadequacy of the statin response and the potential for targeting these particles by additional therapies for further reducing risk among statin-treated individuals. See p 2220.
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Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis: The Randomized Femoral Artery In-Stent Restenosis (FAIR) Trial
As a result of an increasing tendency to stent superficial femoral artery (SFA) lesions, which is associated with not entirely satisfying primary patency rates, the treatment of SFA in-stent restenosis (ISR) has become increasingly important. Drugcoated balloon angioplasty (DCBA) compared with standard balloon angioplasty has shown superior efficacy for de novo lesions. Therefore, DCBA seemed to be the obvious approach for the minimally invasive treatment of SFA ISR. However, available data were poor and did not allow therapeutic decisions. The multicenter, randomized, controlled Femoral Artery In-Stent Restenosis (FAIR) trial demonstrates for the first time that the treatment of SFA ISR with DCBA is associated with lower recurrent restenosis rates and target lesion revascularizations than standard balloon angioplasty at 6 and 12 months. Moreover, clinical improvement of ≥1 Rutherford category at 12 months without the need for target lesion revascularization was observed more often after DCBA. Safety profiles were equivalent between both treatment groups. Therefore, the question of whether DCBA works in an SFA ISR as opposed to de novo SFA lesions can now be answered: Based on the clinical results of the FAIR trial, paclitaxel-coated balloons are as effective in restenotic lesions as in native vessels. A clear treatment recommendation can be made for DCBA in SFA ISR up to 150 mm in length. See p 2230.
Genetic Ablation of Extra Domain A of Fibronectin in Hypercholesterolemic Mice Improves Stroke Outcome by Reducing Thrombo-Inflammation
Ischemic stroke often occurs in the context of comorbid conditions such as hypertension, diabetes mellitus, and hypercholesterolemia. These comorbid conditions are associated with elevated plasma levels of fibronectin-splicing variants containing extra domain A (Fn-EDA). Following the recommendations of the Stroke Therapy Academic Roundtable, we investigated the functional role of Fn-EDA in experimental stroke outcomes in a murine model of hypercholesterolemia, the apolipoprotein E-deficient (Apoe −/− ) mouse. Novel strains of Apoe −/− mice deficient in Fn-EDA and/or Toll-like receptor-4 were generated to assess the mechanistic role of Fn-EDA in transient brain ischemia/reperfusion injury in the context of hypercholesterolemia. We provide evidence for the first time that nonhematopoietic cell-derived Fn-EDA exacerbates adverse stroke outcomes in Apoe −/− mice by promoting cerebral thrombosis and postischemic inflammation through Toll-like receptor-4 expressed on hematopoietic cells. Importantly, we show that targeting Fn-EDA with a specific anti-Fn-EDA antibody 15 minutes after reperfusion significantly improves stroke outcome. The mechanistic insights provided by the present study suggest that plasma Fn-EDA may be a prognostic biomarker for patients at high risk for stroke and that targeting Fn-EDA with specific inhibitors might reduce ischemic/reperfusion brain injury associated with hypercholesterolemia. See p 2237.
